Publications

Journal Article
Research Support, N.I.H., Extramural
Ppublish 440 citations
Electronic publication date
October 6, 2010

View on Pubmed.gov 20622903 | View on doi.org 10.1038/onc.201...

HMGB1 release and redox regulates autophagy and apoptosis in cancer cells.

Search for publications in this journal Oncogene - 29(38):5299-310

Abstract

The functional relationship and cross-regulation between autophagy and apoptosis is complex. In this study we show that the high-mobility group box 1 protein (HMGB1) is a redox-sensitive regulator of the balance between autophagy and apoptosis. In cancer cells, anticancer agents enhanced autophagy and apoptosis, as well as HMGB1 release. HMGB1 release may be a prosurvival signal for residual cells after various cytotoxic cancer treatments. Diminished HMGB1 by short hairpin RNA transfection or inhibition of HMGB1 release by ethyl pyruvate or other small molecules led predominantly to apoptosis and decreased autophagy in stressed cancer cells. In this setting, reducible HMGB1 binds to the receptor for advanced glycation end products (RAGEs), but not to Toll-like receptor 4, induces Beclin1-dependent autophagy and promotes tumor resistance to alkylators (melphalan), tubulin disrupting agents (paclitaxel), DNA crosslinkers (ultraviolet light) and DNA intercalators (oxaliplatin or adriamycin). On the contrary, oxidized HMGB1 increases the cytotoxicity of these agents and induces apoptosis mediated by the caspase-9/-3 intrinsic pathway. HMGB1 release, as well as its redox state, thus links autophagy and apoptosis, representing a suitable target when coupled with conventional tumor treatments.

References

Exp Cell Res. 2006 Nov 1;312(18):3526-38

Antioxid Redox Signal. 2009 Apr;11(4):777-90

Cancer Res. 2008 Mar 1;68(5):1485-94

Science. 1999 Jul 9;285(5425):248-51

Cited by 440 citations (total)

Journal Article

miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy.

Electronic publication date July 11, 2014

Search for publications in this journal Exp Ther Med

Lu Chen [...] Peng Wei et al.

Frequent acquisition of drug resistance is often associated with the chemotherapy of malignant tumors, including osteosarcoma. A number of studies...

Journal Article Research Support, Non-U.S. Gov't

HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer.

Electronic publication date March 30, 2016

Search for publications in this journal Tumour Biol

Yirong Xu [...] Lin Tian et al.

High mobility group box 1 (HMGB1) is associated with tumor progression and a poor prognosis; microtubule-associated protein 1 light chain...

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances